Use este identificador para citar ou linkar para este item: http://rima.ufrrj.br/jspui/handle/20.500.14407/26780
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorCarvalho, Nathália da Silva-
dc.date.accessioned2026-10-26T14:36:43Z-
dc.date.available2026-10-26T14:36:43Z-
dc.date.issued2025-09-26-
dc.identifier.citationCARVALHO, Nathália da Silva. Caracterização das imunossupressões local e sistêmica em cães com neoplasias melanocíticas. 2025. 58 f. Tese (Doutorado em Medicina Veterinária) - Instituto de Veterinária, Universidade Federal Rural do Rio de Janeiro, Seropédica, 2025.pt_BR
dc.identifier.urihttp://rima.ufrrj.br/jspui/handle/20.500.14407/26780-
dc.description.abstractOs mecanismos de evasão tumoral têm sido o cerne de inúmeras pesquisas no intuito de se encontrar novos alvos para terapias imunológicas. Melanomas são neoplasias imunogênicas e a observação da regressão parcial ou completa associada à marcada infiltração por linfócitos T contribuem com esta afirmativa, entretanto, esse tipo de neoplasia também apresenta diversos mecanismos de evasão tumoral. Além disso, os componentes do microambiente tumoral influenciam de forma positiva ou negativa no desenvolvimento da neoplasia. A polarização de macrófagos M2 no infiltrado inflamatório tem ação pró-tumorigênica, pois secretam citocinas com ação anti- inflamatória que estimulam a neovascularização local. O objetivo deste trabalho foi caracterizar as imunossupressões local e sistêmica em cães diagnosticados com neoplasia melanocítica no Setor de Anatomia Patológica da Universidade Federal Rural do Rio de Janeiro (SAP/UFRRJ). Foram realizadas análises imuno-histoquímicas para pesquisar a contagem de subpopulações de macrófagos M2 com o uso do anticorpo anti- CD-206, que possam estar infiltrados na neoplasia, nos linfonodos regionais e, quando provenientes de necropsia, nos demais órgãos (baço, pulmão, encéfalo), além da fração de crescimento celular ou índice de Ki-67. Foram utilizados blocos de parafina do arquivo SAP com fragmentos de neoplasias melanocíticas em cães (orais e cutâneas) e os respectivos linfonodos regionais. Para pesquisa em órgãos internos, foram priorizadas necropsias de cães previamente diagnosticados e doados para estudo com termo de consentimento. Foram coletados dados referentes a 25 neoplasias melanocíticas em cães, sendo quatro melanocitomas e, os demais, melanomas. Com relação à epidemiologia, 9 acometeram fêmeas, 16 machos e todos os animais eram adultos entre sete e 17 anos de idade. Treze casos estavam localizados na pele e 11 na cavidade oral, havia um caso sem identificação do sítio de origem. Entre os melanomas, 19 eram do tipo misto, quatro epitelioides e dois fusiformes. Em 19 dos 25 casos, o pleomorfismo apresentou-se moderado a acentuado e, em 15 casos, foram observadas mais de 10 figuras de mitose em 10 campos de maior aumento (Obj. 40x, 2,37 mm2). A imuno-histoquímica com o anticorpo Ki-67 apresentou imunorreatividade em 20 casos, todos da variante maligna. Em 13 casos foi observada fração de crescimento elevada. Sete destes, com origem cutânea e os outros 6, na cavidade oral. A expressão de CD206 foi observada em 21 casos, com distribuição intratumoral e peritumoral. Destes, 14 com origem cutânea e outros 7, na cavidade oral. Desta maneira, pôde-se demonstrar indícios de alterações e ajustes locais e/ou sistêmicos em cães com neoplasias melanocíticas e estabelecer novos marcadores de prognóstico, como o CD206, de maneira a complementar e tornar mais preciso o prognóstico dessas neoplasias em cães, além de subsidiar pesquisas neste campo em humanos.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal Rural do Rio de Janeiropt_BR
dc.subjectimunomodulaçãopt_BR
dc.subjectfração de crescimentopt_BR
dc.subjectmacrófagospt_BR
dc.subjectmelanomapt_BR
dc.subjectimmunomodulation,pt_BR
dc.subjectgrowth fractionpt_BR
dc.subjectmacrophagespt_BR
dc.subjectmelanomapt_BR
dc.titleCaracterização das imunossupressões local e sistêmica em cães com neoplasias melanocíticaspt_BR
dc.title.alternativeCharacterization of local and systemic immunosuppression in dogs with melanocytic neoplasmsen
dc.typeTesept_BR
dc.description.abstractOtherTumor evasion mechanisms have been the focus of numerous studies aimed at finding new targets for immunological therapies. Melanomas are immunogenic neoplasms, and the observation of partial or complete regression associated with marked T lymphocyte infiltration supports this assertion. However, this type of neoplasm also exhibits several tumor evasion mechanisms. Furthermore, components of the tumor microenvironment positively or negatively influence neoplasm development. The polarization of M2 macrophages in the inflammatory infiltrate has a pro-tumorigenic effect, as they secrete cytokines with anti-inflammatory action that stimulate local neovascularization. The objective of this study was to characterize local and systemic immunosuppression in dogs diagnosed with melanocytic neoplasia in the Pathological Anatomy Department of the Federal Rural University of Rio de Janeiro (SAP/UFRRJ). Immunohistochemical analyses were performed to determine the number of M2 macrophage subpopulations using anti-CD-206 antibody. These subpopulations may be infiltrated in the neoplasia, regional lymph nodes, and, when obtained at necropsy, other organs (spleen, lung, brain), in addition to the cell growth fraction or Ki-67 index. Paraffin blocks from the SAP archive were used to study fragments of melanocytic neoplasms in dogs (oral and cutaneous) and their respective regional lymph nodes. For internal organ research, necropsies of previously diagnosed dogs donated for study with informed consent were prioritized. Data were collected on 25 melanocytic neoplasms in dogs, four melanocytomas and the others melanomas. Regarding epidemiology, nine affected females, 16 males, and all animals were adults between seven and 17 years of age. Thirteen cases were located in the skin and 11 in the oral cavity, there was a case without identification of the site of origin. Among the melanomas, 19 were mixed, four epithelioid, and two spindle-shaped. In 19 of the 25 cases, pleomorphism was moderate to severe, and in 15 cases, more than ten mitotic figures were observed in ten high- power fields (Obj. 40x, 2,37 mm2). Immunohistochemistry with the Ki-67 antibody showed immunoreactivity in 20 cases, all of the malignant variant. A high growth fraction was observed in 13 cases. Seven of these originated in the skin and the other six in the oral cavity. CD206 expression was observed in 21 cases, with intratumoral and peritumoral distribution. Of these, 14 originated in the skin and the other seven in the oral cavity. Thus, it was possible to demonstrate evidence of local and/or systemic alterations and adjustments in dogs with melanocytic neoplasms and establish new prognostic markers, such as CD206, to complement and improve the prognosis of these neoplasms in dogs, as well as to support research in this field in humans.en
dc.contributor.advisor1Carvalho, Vivian de Assunção Nogueira-
dc.contributor.advisor1IDhttps://orcid.org/0000-0002-4034-9675pt_BR
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/6012855368365110pt_BR
dc.contributor.advisor-co1Costa, Samay Zillmann Rocha-
dc.contributor.advisor-co1IDhttps://orcid.org/0000-0001-7410-7351pt_BR
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/7071350800206490pt_BR
dc.contributor.referee1Carvalho, Vivian de Assunção Nogueira-
dc.contributor.referee1IDhttps://orcid.org/0000-0002-4034-9675pt_BR
dc.contributor.referee1Latteshttp://lattes.cnpq.br/6012855368365110pt_BR
dc.contributor.referee2Costa, Samay Zillmann Rocha-
dc.contributor.referee2IDhttps://orcid.org/0000-0001-7410-7351pt_BR
dc.contributor.referee2Latteshttp://lattes.cnpq.br/7071350800206490pt_BR
dc.contributor.referee3Peixoto, Tiago da Cunha-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/2092167505993680pt_BR
dc.contributor.referee4Oliveira, Mariana Correia-
dc.contributor.referee4Latteshttp://lattes.cnpq.br/5852122599797953pt_BR
dc.contributor.referee5Leal, Paula Velozo-
dc.contributor.referee5Latteshttp://lattes.cnpq.br/9326236207164636pt_BR
dc.creator.IDhttps://orcid.org/0000-0002-9053-3710pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/1539631107187406pt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentInstituto de Veterináriapt_BR
dc.publisher.initialsUFRRJpt_BR
dc.publisher.programPrograma de Pós-Graduação em Medicina Veterinária (Patologia e Ciências Clínicas)pt_BR
dc.relation.referencesABBAS, A. K.; LICHTMAN, A. H.; PILLAI, S. Imunologia celular e molecular. 8. ed. Rio de Janeiro: Elsevier, 2015. ATHERTON, M. J. et al. Cancer immunology and canine malignant melanoma: a comparative review. Veterinary Immunology and Immunopathology, v. 169, p. 15– 26, 2016. BABA, A. I.; CÂTOI, C. Comparative Oncology. Bucharest: Publishing House of the Romanian Academy, 2007. BALLAS, Z. K. et al. Role of NK cell subsets in organ-specific murine melanoma metastasis. PloS One, v. 8, n. 6, p. e65599, 2013. BARROS, C. S. L. Guia da técnica de necropsia dos mamíferos domésticos. Santa Maria: [s.n.], 1998. BERGIN, I. L. et al. Prognostic evaluation of Ki67 threshold value in canine oral melanoma. Veterinary Pathology, v. 48, n. 1, p. 41-53, 2011. BERGMAN, P. J. Canine oral melanoma. Clinical Techniques in Small Animal Practice, v. 22, n. 2, p. 55-60, 2007. BERGMAN, P. J. et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research, v. 9, n. 4, p. 1284-1290, 2003. BERGMAN, P. J.; SELMIC, L. E.; KENT, M. S. Melanoma. In: VAIL, D. M.; THAM, D. H.; LIPTAK, J. M. (ed.). Withrow and MacEwen's small animal clinical oncology. 6. ed. St. Louis: Elsevier, 2019. p. 367-381. BILLINGS, S. D. Tumor and tumor-like conditions of the skin. In: GOLDBLUM, J. R.; LAMPS, L. W.; MCKENNEY, J. K.; MYERS, J. L. (ed.). Rosai and Ackerman's surgical pathology. 11. ed. Amsterdam: Elsevier, 2018. p. 45–143. BISWAS, S. K.; MANTOVANI, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, v. 11, p. 889, 2010. BISWAS, S. K.; ALLAVENA, P.; MANTOVANI, A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars in Immunopathology, v. 35, p. 585–600, 2013. BOECKE, A. et al. TNF-1 receptor adapter protein FAN mediates TNF-induced B16 melanoma motility and invasion. British Journal of Cancer, v. 109, p. 422–432, 2013. BOZDOGAN, N. et al. FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study. [S.l.]: [s.n.], 2010. BROCKLEY, L. K.; COOPER, M. A.; BENNETT, P. F. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal, v. 61, n. 1, p. 25-31, 2013. BRONKHORST, I. H. G. et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Investigative Ophthalmology and Visual Science, v. 52, n. 2, p. 643–650, 2011. BROWN, C. C.; BAKER, D. C.; BARKER, I. K. Alimentary system. In: MAXIE, G. (ed.). Pathology of domestic animals. 5. ed. v. 1. Philadelphia: Elsevier, 2007. p. 1- 296. CAMARGO, L. P.; CONCEIÇÃO, L. G.; DOS SANTOS COSTA, P. R. Neoplasias melanocíticas cutâneas em cães: estudo retrospectivo de 68 casos (1996-2004). Brazilian Journal of Veterinary Research and Animal Science, v. 45, n. 2, p. 138- 152, 2008. CAMERINO, M. et al. Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: a retrospective study on 68 cases (2010–2020). Veterinary and Comparative Oncology, v. 20, p. 189–197, 2022. CARVALHO, N. S. et al. Aspectos anatomopatológicos e avaliação da fração de crescimento (Ki-67) das neoplasias melanocíticas diagnosticadas em cães no setor de anatomia patológica da UFRRJ (1999-2020). [S.l.]: [s.n.], 2021. CONCEIÇÃO, L. G.; LOURES, F. H. Sistema tegumentar. In: SANTOS, R. L.; ALESSI, A. C. (ed.). Patologia veterinária. 2. ed. Rio de Janeiro: Roca, 2016. p. 407- 486. CONDEELIS, J.; POLLARD, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, v. 124, n. 2, p. 263-266, 2006. COLMENARES-ROLDÁN, L. M.; LOPERA, M. M. V.; SUAZA, G. A. V. Melanoma lentiginoso acral: una variante de melanoma maligno de especial interés en Colombia. Iatreia, v. 21, n. 4, p. 386-397, 2008. COWELL, R. L.; VALENCIANO, A. C. Diagnostic cytology and hematology of the dog and cat. 4. ed. Missouri: Elsevier, 2014. p. 32-34. DE NARDO, D. G.; COUSSENS, L. M. Inflammation and breast cancer: balancing immune response crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research, v. 9, p. 1-10, 2007. DOBSON, J. M. Breed-predispositions to cancer in pedigree dogs. International Scholarly Research Notices, v. 2013, p. 1-23, 2013. DUCHROW, M. et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Proliferation, v. 29, n. 1, p. 1-12, 1996. DUMMER, W. et al. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Research, v. 5, n. 1, p. 67–68, 1995. DUNCAN, L. M. et al. Low-CSD melanoma (superficial spreading melanoma). In: ELDER, D. E. et al. (ed.). WHO classification of skin tumors. 4. ed. Lyon: International Agency for Research on Cancer/World Health Organization, 2018. p. 76- 77. ELDER, D. E. et al. WHO classification of skin tumours. Lyon: IARC/WHO, 2018. FOURNEL-FLEURY, C. et al. Growth fractions in canine non-Hodgkin's lymphomas as determined in situ by the expression of the Ki-67 antigen. Journal of Comparative Pathology, v. 117, n. 1, p. 61-72, 1997. FUJIMURA, T.; AIBA, S. Significance of immunosuppressive cells as a target for immunotherapies in melanoma and non-melanoma skin cancers. Biomolecules, v. 10, n. 8, p. 1087, 2020. GARMA-AVIÑA, A.; VALLI, V. E.; LUMSDEN, J. H. Cutaneous melanomas in domestic animals. Journal of Cutaneous Pathology, v. 8, n. 1, p. 3-24, 1981. GERDES, J. et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. Journal of Immunology, v. 133, n. 4, p. 1710-1715, 1984. GERLINI, G. et al. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. American Journal of Pathology, v. 165, n. 6, p. 1853–1863, 2004. GILLARD, M. et al. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell & Melanoma Research, v. 27, n. 1, p. 90-102, 2014. GOLA, C. et al. Hypoxia-associated markers in the prognosis of oral canine melanoma. Veterinary Pathology, v. 61, n. 5, p. 721-731, 2024. GOLDSCHMIDT, M. H.; GOLDSCHMIDT, K. H. Epithelial and melanocytic tumors of the skin. In: MEUTEN, D. J. (ed.). Tumors in domestic animals. 5. ed. Ames: Wiley Blackwell, 2020. p. 123-131. GROSS, T. L. et al. Doenças de pele do cão e do gato: diagnóstico clínico e histopatológico. 2. ed. [S.l.]: [s.n.], 2009. GRANDI, F.; RONDELLI, M. C. H. Neoplasias cutâneas. In: DALECK, C. R.; NARDI, A. B. de. (ed.). Oncologia em cães e gatos. 2. ed. São Paulo: Roca, 2016. p. 339-360. GWAK, J. M. et al. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PloS One, v. 10, n. 4, p. e0125728, 2015. HASSAN, B. B. et al. Cutaneous tumors in dogs: a retrospective epidemiological and histological study of 112 cases. Advances in Animal and Veterinary Sciences, v. 10, n. 1, p. 170-182, 2022. HAHN, K. A. et al. Canine oral malignant melanoma: prognostic utility of an alternative staging system. Journal of Small Animal Practice, v. 35, p. 251–256, 1994. HAUCK, M. L. Tumors of the skin and subcutaneous tissues. In: WITHROW, S. J.; VAIL, D. M.; PAGE, R. L. (ed.). Withrow and MacEwen’s small animal clinical oncology. 5. ed. Saint Louis: Saunders Elsevier, cap. 18, p. 389-393, 2013.. HUANG, L. et al. Correlation of tumor-infiltrating immune cells of melanoma with overall survival by immunogenomic analysis. Cancer Medicine, v. 9, n. 22, p. 8444- 8456, 2020. IDIKIO, H. A. Immunohistochemistry in diagnostic surgical pathology: contributions of protein life-cycle, use of evidence-based methods and data normalization on interpretation of immunohistochemical stains. International Journal of Clinical and Experimental Pathology, v. 3, n. 2, p. 169, 2009. IUSSICH, S. et al. PDGFRs expression in dogs affected by malignant oral melanomas: correlation with prognosis. Veterinary Comparative Oncology, v. 15, p. 462–469, 2017. ITAKURA, E. et al. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Modern Pathology, v. 24, n. 6, p. 801–809, 2011. JONES, T. C.; HUNT, R. D.; KING, N. W. A pele e seus apêndices. Patologia Veterinária. São Paulo: Manole, p. 831-886, 2000. KIUPEL, M.; TESKE, E.; BOSTOCK, D. Prognostic factors for treated canine malignant lymphoma. Veterinary Pathology, v. 36, n. 4, p. 292-300, 1999. KLAPPERICH, M. E.; BOWEN, G. M.; GROSSMAN, D. Current controversies in early-stage melanoma: questions on management and surveillance. Journal of the American Academy of Dermatology, v. 80, n. 1, p. 15-25, 2019. KUBBUTAT, M. H. et al. Epitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki- 67 protein). Journal of Clinical Pathology, v. 47, n. 6, p. 524-528, 1994. LACROUX, C. et al. Study of canine cutaneous melanocytic tumours: evaluation of histological and immunohistochemical prognostic criteria in 65 cases. Revue de Médecine Vétérinaire, v. 163, p. 393–401, 2012. LAPRIE, C. et al. MIB-1 immunoreactivity correlates with biologic behaviour in canine cutaneous melanoma. Veterinary Dermatology, v. 12, n. 3, p. 139-147, 2001. LAVER, T. et al. Post-surgical outcome and prognostic factors in canine malignant melanomas of the haired skin: 87 cases (2003–2015). Canadian Veterinary Journal, v. 59, n. 9, p. 981, 2018. LEE, J. H. et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clinical Cancer Research, v. 11, n. 1, p. 107–112, 2005. 45 LEIGNADIER, J. et al. CD8 engineered cytotoxic T cells reprogram melanoma tumor environment. Oncoimmunology, v. 5, n. 3, p. e1086861, 2016. LIN, E. Y. et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Research, v. 66, p. 11238-11246, 2006. MANTOVANI, A. et al. Macrophages in cancer: tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization. Annual Review of Pathology: Mechanisms of Disease, v. 17, p. 1-25, 2022. MANZAN, R. M. et al. Considerações sobre melanoma maligno em cães: uma abordagem histológica. Boletim de Medicina Veterinária, v. 1, n. 1, 2005. MEUTEN, D. J. (ed.). Tumors in domestic animals. 5. ed. Ames: John Wiley & Sons, 2016. MILLANTA, F. et al. Proliferation activity in oral and cutaneous canine melanocytic tumours: correlation with histological parameters, location, and clinical behaviour. Research in Veterinary Science, v. 73, n. 1, p. 45-51, 2002. MILLS, C. D. M1 and M2 macrophages: oracles of health and disease. Critical Reviews in Immunology, v. 32, n. 6, p. 463-488, 2012. MODIANO, J. F.; RITT, M. G.; WOJCIESZYN, J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine, v. 13, p. 163-174, 1999. MOELLER, A. et al. Challenges and prospects of CSF1R targeting for advanced malignancies. American Journal of Cancer Research, v. 13, n. 7, p. 3257, 2023. MONTEIRO, L. N. et al. Tumour-associated macrophages: relation with progression and invasiveness, and assessment of M1/M2 macrophages in canine mammary tumours. Veterinary Journal, v. 234, p. 119-125, 2018. MOZZILLO, N. et al. Superficial and deep lymph node dissection for stage III cutaneous melanoma: clinical outcome and prognostic factors. World Journal of Surgical Oncology, v. 13, n. 1, p. 1-8, 2015. NAKAGAWA, T. et al. Mitotic index is the most powerful prognostic factor in patients with primary cutaneous malignant melanoma. Japanese Journal of Clinical Oncology, v. 41, n. 2, p. 214-219, 2011. NAKAMURA, Y. et al. Inhibition of IL-10 signaling enhances the efficacy of anti-PD-1 immunotherapy in melanoma. Journal of Clinical Investigation, v. 130, n. 2, p. 904– 914, 2020. NISHIYA, A. T. et al. Comparative aspects of canine melanoma. Veterinary Sciences, v. 3, n. 1, p. 7, 2016. O’BRIEN, M. G. et al. Treatment of oral malignant melanoma in dogs by hypofractionated radiation therapy and platinum-based chemotherapy. Veterinary Radiology & Ultrasound, v. 36, n. 4, p. 293-296, 1995. OLIVEIRA, F. N. et al. Oral melanoma in dogs: retrospective study of 32 cases (2002– 2014). Pesquisa Veterinária Brasileira, v. 36, p. 7, p. 669-673, 2016. OLIVEIRA, G. R. et al. Oral melanoma in dogs: epidemiological study and prognostic factors. Ciência Rural, v. 51, n. 12, 2021. OTTNIN, R. C. et al. Histopathology of preclinical mouse models of prostate cancer: applications to drug development. Toxicologic Pathology, v. 45, n. 4, p. 456-470, 2017. PAOLONI, M. C. et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics, v. 10, p. 625, 2009. PAVAN, T. L. et al. Canine melanoma: immunohistochemical expression of CD3, CD20, CD79a, and MUM1. Brazilian Journal of Veterinary Research and Animal Science, v. 59, p. e184582, 2022. PHILLIPS, B. S. et al. Histopathological and immunohistochemical assessment of melanocytic neoplasms in gray horses. Veterinary Pathology, v. 56, n. 2, p. 221–228, 2019. PLATT, S. R. et al. Neurological signs caused by a trigeminal malignant melanoma in a dog. Journal of Small Animal Practice, v. 38, p. 444–448, 1997. PORCELLATO, I. et al. Tumour-infiltrating lymphocytes in canine melanocytic tumours: an investigation on the prognostic role of CD3+ and CD20+ lymphocytic populations. Veterinary and Comparative Oncology, v. 17, n. 3, p. 311-319, 2019. QUEIROGA, F. L.; PINTO, C.; PEREIRA, C. Oral and cutaneous melanocytic tumours in the dog: a clinical, pathological, and immunohistochemical study. Journal of Veterinary Medicine Series A, v. 52, n. 7, p. 345–351, 2005. RAMOS-VARA, J. A. et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Veterinary Pathology, v. 37, n. 6, p. 597–608, 2000. REBHUN, R. B.; THAMM, D. H. Biology and treatment of canine osteosarcoma. Veterinary Surgery, v. 39, n. 1, p. 102-107, 2010. REIS, L. F. L. Oncogenômica: do câncer à medicina de precisão. São Paulo: Atheneu, 2016. RICHARDS, H. G. et al. Central nervous system metastases in malignant melanoma: correlation with ki67. Journal of Clinical Pathology, v. 39, n. 8, p. 822-826, 1986. RITT, M. G. et al. Immunohistochemical detection of p53 and p21/waf-1 in canine malignant melanoma. Veterinary Pathology, v. 37, p. 146-153, 2000. RODRIGUES, A. M. et al. Diagnóstico histopatológico de neoplasias melanocíticas cutâneas caninas: estudo de 34 casos. Ciência Rural, v. 38, n. 5, p. 1359-1365, 2008. RODRIGUEZ, F. J. et al. Canine gliomas: a comparative study. Veterinary Pathology, v. 49, n. 4, p. 561-579, 2012. RUNGHI, R. et al. Macrophages, their modulation and the potential use of RNA interference in their reprogramming strategy: a review. Veterinary and Comparative Oncology, v. 15, p. 6-21, 2017. SARLI, G. et al. Cell proliferation in canine and feline melanocytic neoplasms: relationship with histological parameters and clinical behavior. Research in Veterinary Science, v. 72, p. 65-72, 2002. SCARPA, F. et al. A new predictive score for dogs with oral melanoma: results from a multicenter study. Cancers, v. 12, n. 7, p. 1688, 2020. SCARPA, F. et al. Prognostic value of Ki67 and MCM7 expression in canine oral melanomas. Veterinary Journal, v. 215, p. 18-24, 2016. SELVARAJAN, S. et al. Distribution of cell cycle regulatory proteins in canine melanocytic tumors: associations with proliferation and clinicopathological variables. Veterinary Journal, v. 196, p. 208-216, 2013. SERRA, M. et al. Evaluation of Ki67 and PCNA expression in canine melanocytic tumors. Veterinary Pathology, v. 48, p. 132-137, 2011. SHENG, J. et al. The efficacy of cancer immunotherapy is negatively regulated by Foxp3+ regulatory T cells in murine melanoma. Biochemical and Biophysical Research Communications, v. 505, n. 3, p. 682-688, 2018. SINGH, S. K. et al. Natural killer T cell-targeted immunotherapy mediates melanoma regression. Journal of Clinical Investigation, v. 112, n. 8, p. 1211-1220, 2003. SMEDLEY, R. C. et al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Veterinary Pathology, v. 48, n. 1, p. 54-72, 2011. SMEDLEY, Rebecca C.; SEBASTIAN, Kimberley; KIUPEL, Matti. Diagnosis and prognosis of canine melanocytic neoplasms. Veterinary Sciences, v. 9, n. 4, p. 175, 2022. SMEDLEY, Rebecca C. et al. Diagnosis and histopathologic prognostication of canine melanocytic neoplasms: A consensus of the Oncology-Pathology Working Group. Veterinary and Comparative Oncology, v. 20, n. 4, p. 739-751, 2022. SMITH, S. H.; GOLDSCHMIDT, M. H.; MCMANUS, P. M. A comparative review of melanocytic neoplasms. Veterinary Pathology, v. 39, p. 651–678, 2002. SOARES, N. P. et al. Distribuição de neoplasias melanocíticas em cães diagnosticadas em hospital veterinário no Ceará. Revista Brasileira de Higiene e Sanidade Animal, v. 15, n. 1, p. 16-27, 2021. SPINOLA, G. et al. Cutaneous melanoma in dogs: a retrospective analysis of 65 cases (2011-2016). Revista de Educação Continuada em Medicina Veterinária e Zootecnia do CRMV-SP, v. 19, n. 2, p. 63-70, 2021. STERMAN, D. et al. Mesenchymal stem cells can serve as tumor stroma. Stem Cells, v. 25, n. 7, p. 1803-1810, 2007. STOCKHAM, S. L.; SCOTT, M. A. Fundamentals of veterinary clinical pathology. 2. ed. Iowa: Blackwell, 2008. STRAHL, O. et al. Tumor-associated macrophages in canine malignant melanoma: correlation with histopathological and clinical parameters. Veterinary Pathology, v. 63, n. 1, p. 123-134, 2026. SUZUKI, Y. et al. Early lung cancer diagnosis by means of small pulmonary nodules detection in computer tomography images. Cancer, v. 89, n. 11, p. 2444-2451, 2000. TARONE, L. et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research, v. 25, n. 9, p. 2826-2835, 2019. TARDITO, S. et al. Macrophage M1/M2 polarization and rapamycin-induced immunosuppression. International Journal of Oncology, v. 40, p. 935-944, 2012. TURAN, T. et al. Tumor-associated macrophages in cutaneous melanoma: histopathological markers for prognosis. Pathology, v. 52, p. 584-590, 2020. VAIL, D. M.; THAMM, D. H.; LIPTAK, J. M. (ed.). Withrow and MacEwen’s small animal clinical oncology. 6. ed. St. Louis: Elsevier, 2019. VAN HERWAARDEN, A. E. et al. Intratumoral localization of myeloid-derived suppressor cells in human melanoma. Human Pathology, v. 50, p. 43-49, 2016. VAN HERWAARDEN, A. E. et al. Myeloid-derived suppressor cells in immune responses during melanoma progression. Oncoimmunology, v. 6, n. 7, p. e1338996, 2017. VERDEGAAL, E. M. et al. Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma. Cancer Research, v. 67, n. 15, p. 7565-7573, 2007. WOLCHOK, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical Cancer Research, v. 15, n. 23, p. 7412–7420, 2009. WOLCHOK, J. D. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New England Journal of Medicine, v. 372, n. 4, p. 311–319, 2015. WU, A. et al. Expression of MHC I and II and PD-L1 in primary canine oral malignant melanoma and lymph node metastases. Veterinary and Comparative Oncology, v. 18, n. 3, p. 330-340, 2020. XIN, W. et al. Diagnostic immunohistochemistry of common and selected rare neoplasms encountered in bone and soft tissue pathology. Archives of Pathology & Laboratory Medicine, v. 138, n. 12, p. 1564-1591, 2014. ZHANG, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PloS One, v. 7, n. 12, p. e50946, 2012.pt_BR
dc.subject.cnpqMedicina Veterináriapt_BR
Aparece nas coleções:Doutorado em Medicina Veterinária (Patologia e Ciências Clínicas)

Se for cadastrado no RIMA, poderá receber informações por email.
Se ainda não tem uma conta, cadastre-se aqui!

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
2025 - Nathalia da Silva Carvalho.pdf1,63 MBAdobe PDFAbrir


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.